Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03801395 · ClinicalTrials.gov registry record
PCD New Gene Discovery
A clinical trial, sponsored by Vanderbilt University Medical Center.
- Completed
- Registry status
- 10
- Enrollment target
NCT03801395: Completed study, sponsored by Vanderbilt University Medical Center.
NCT03801395 is a clinical trial that has completed, run by Vanderbilt University Medical Center. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03801395 has completed, sponsored by Vanderbilt University Medical Center.
- COMPLETED
- Registry status
- 10 participants
- Enrollment target
Study Summary
This is a new gene discovery program for individuals with PCD who do not have a specific genetic etiology identified. Research procedures involve a single blood draw from the affected individual and from unaffected family members in an effort to identify new genetic targets.
Primary Outcome
Blood will be obtained for DNA analysis and identification of new PCD genes. Genetic analysis will be done by whole exome sequencing
Interventions
- OTHER There is no intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-01-07 |
| Est. Completion | 2024-11-20 |
What the finished NCT03801395 record still lists
NCT03801395 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which There is no intervention is the first listed.
NCT03801395 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03801395 about?
NCT03801395 is a clinical study titled "PCD New Gene Discovery". This is a new gene discovery program for individuals with PCD who do not have a specific genetic etiology identified. Research procedures involve a single blood draw from the affected individual and from unaffected family members in an effort to identify new genetic targets.
What is the current status of trial NCT03801395?
This trial is currently completed. The enrollment target is 10 participants. The study started on 2019-01-07. Estimated completion is 2024-11-20.
What interventions are being tested in trial NCT03801395?
The interventions under investigation include: There is no intervention (OTHER).
Who is sponsoring clinical trial NCT03801395?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI